-
FDA pointedly rejects Intellipharma’s opioid painkiller
pharmafile
September 27, 2017
The FDA has been very public in its stance that it will look to gain the upper hand in bringing the opioid epidemic under control, within its own remit.
-
FDA conducts major global operation to protect consumers from potentially dangerous prescription dru
worldpharmanews
September 27, 2017
The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines
-
Allergan Receives Refusal to File Letter from FDA for Vraylar
americanpharmaceuticacreview
September 26, 2017
Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.
-
Medtronic’s next generation spinal cord stimulator cleared by FDA
biospectrumasia
September 21, 2017
The world's smallest SCS, the Intellis device offers activity tracking and personalized pain relief
-
GlaxoSmithKline, needing a sales surge, wins FDA nod for $1B-plus prospect Trelegy
fiercepharma
September 20, 2017
Bracing for generic competition to its top-selling Advair, GlaxoSmithKline nabbed an FDA approval for the "closed-triple" COPD therapy Trelegy Ellipta.
-
Roche added to the hold group by FDA for combo immunotherapy trials
pharmafile
September 20, 2017
The FDA has been working to make sure certain immunotherapy trials being placed on full or partial hold.
-
Review of 2017 H1 of the biological & pharmaceutical industries
en-cphi.cn
September 19, 2017
New drug approval reached a historic high, while industry M&A boom fell back
-
DelMar Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083
americanpharmaceuticacreview
September 19, 2017
Twenty-four patients will be enrolled under the first phase of the VAL-083 REPROVe Trial with top line results expected within 18-24 months from trial initiation of patient treatment.
-
Bayer lymphoma treatment speeds to FDA approval
pharmafile
September 19, 2017
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came to the judgement that the drug should be brought to patients with relapsed follicular lymphoma.
-
FDA puts clinical hold on Cellectis' CAR-T cell therapies
biospectrumasia
September 19, 2017
Cellectis said it is working with clinical trial investigators and the FDA to resume the trials with an amended trial protocol that includes a lower dose of UCART123.